Evidence map›Paper›PMID 29516230›Full record

ReviewHeart failure reviews2018

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Anne Pernille Ofstad, Dan Atar, Lars Gullestad, Gisle Langslet, Odd Erik Johansen

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation.Journal of cardiovascular development and disease · 2022
    Review
  14. Variability in Estimated Modelled Insulin Secretion.Journal of diabetes science and technology · 2022
    Article
  15. Article
  16. Review
  17. Review
  18. Journal of diabetes and metabolic disorders · 2021
    Review
  19. Heart failure and diabetes: role of ATM.Current opinion in pharmacology · 2020
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Anne Pernille OfstadBærum Hospital, Vestre Viken HF, Rud, Norway. Annepernille@hotmail.com.ORCID 0000-0003-2714-0102
Dan AtarDepartment of Cardiology B, Oslo University Hospital, Ullevål, Oslo, Norway.
Lars GullestadFaculty of Medicine, University of Oslo, Oslo, Norway.
Gisle LangsletRikshospitalet, Lipid Clinic, Oslo University Hospital, Oslo, Norway.
Odd Erik JohansenBærum Hospital, Vestre Viken HF, Rud, Norway.
Oslo University Hospital · NOVestre Viken Hospital Trust · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes and heart failure (HF) are both global epidemics with tremendous costs on society with increased rates of HF hospitalizations and worsened prognosis when co-existing, making it a significant "deadly duo." The evidence for pharmacological treatment of HF in patients with type 2 diabetes mellitus (T2DM) stems typically from either subgroup analyses of patients that were recruited to randomized controlled trials of HF interventions, usually in patients with reduced ejection fraction (EF), or from subgroup analyses of HF patients recruited to cardiovascular (CV) outcome trials (CVOT) of glucose lowering agents involving patients with T2DM. Studies in patients with HF with preserved EF are sparse. This review summarizes the literature on pathophysiology and interventions aiming to reduce the HF burden in T2DM and includes HF trials of ACEi, digoxin, β-blocker, ARB, I

Indexed as

Cardiovascular AgentsComorbidityDiabetes Mellitus, Type 2Global HealthHeart FailureHumansHypoglycemic AgentsPrevalencePrognosisRisk FactorsStroke VolumeCardiovascular AgentsHypoglycemic AgentsDiabetes mellitusGlucose loweringHeart failureReview

Identifiers

PMID29516230
PMCPMC5937871
OpenAlexW2790573022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.